

PERSONAL DETAILS

Name M. Amer Khatib

Home Address P.O. Box 830035
Shemisani 11183
Amman - Jordan
Telephone (962) 6 5627833
Cellular (962)796780003
makhatib@pol.net

Date & Place of Birth June 12,1970, Amman, Jordan

Nationality Jordanian

Marital Status Married

Languages Arabic and English

CURRENT POSITION

Assistant Professor in Medicine, University of Jordan, School of Medicine
Consultant in Gastroenterology and Hepatology

Consultant Hepatologist, King Hussien Cancer Center

ACADEMIC ACTIVITIES

1. International editorial board: Hepatogastrohepatology Journal
2. Reviewer, Jordan Medical Journal
3. Founder of Celiac disease Foundation of Jordan (under process)
4. Faculty member in International Society of Surgical Oncology (ISSO)

EDUCATION

1987-1993 Faculty of medicine, University of Jordan,
Amman-Jordan.
Graduation Date: June 13, 1993.
M.B; B.S (MD) degree in Medicine and Surgery.

POSTGRADUATE TRAINING

July 2001-June 2002 Mayo Clinic Arizona, Scottsdale, AZ
Fellowship in Hepatology and Transplant Medicine
Graduation Date: June 13, 2002

July 1998-June 2001 The Western Pennsylvania Hospital, Pittsburgh, PA
 Temple University clinical campus
 Fellowship in Gastroenterology
 Graduation Date: June 15, 2001

July 1995-June 1998 The Western Pennsylvania Hospital, Pittsburgh, PA.
 Temple University clinical campus
 Residency in Internal Medicine.
 Graduation Date: June 13, 1998.

July 1993-June 1994 Al-Basheir Hospital, Amman, Jordan
 Rotating internship in the fields of Internal Medicine,
 OBGYN, Surgery, Pediatrics and Emergency
 Medicine.

PROFESSIONAL CERTIFICATION

Diplomate, American Board of Gastroenterology, certified 2001
 Diplomate, American Board of Internal Medicine, certified 1998 # 181562
 UNOS/ Transplant physician certification, certified 2002
 Jordanian Board in Gastroenterology 2003
 ECFMG, certified 1995 # 0-502-694-3
 Advanced cardiac life support (ACLS) 1995

MEMBERSHIPS & AFFILIATIONS

Mayo Clinic Alumni Association
 American College of Physicians (ACP)
 American Society of Transplantation (AST)
 American College of Gastroenterology (ACG)
 American Society of Gastrointestinal Endoscopy (ASGE)
 American Association for The Study of Liver Diseases (AASLD)
 Pennsylvania Gastroenterology Society (PGS)
 Jordanian Medical Association
 Jordanian Gastroenterological Association
 International Society of Surgeons and Gastroenterologists

GRANTS & AWARDS

The American Association for the Study of Liver Diseases AASLD/ Schering
 advanced fellowship award with \$50,000 grant April 5, 2001
 WPH Service recognition award June 22, 2001
 AMA Physician recognition award 2003

LICENSURE

Pennsylvania
Arizona
Missouri
Kansas
Jordan

PROCEDURES EXPERIENCE:

Certified in all procedures required by ABIM

Diagnostic & Therapeutic Endoscopic Procedures Including:

- Upper GI Endoscopy, Esophageal and pyloric balloon dilatations, stenting, variceal banding, sclerotherapy.
- Push Enteroscopy
- Colonoscopy; polypectomy, using APC.
- ERCP, sphincterotomy, dilatation, biopsy / brushings, stone crushing & extraction, stenting & needle knife.
- Liver Biopsies
- Motility studies.
- Stenting for GI malignancies (metallic) Colonic, small bowel and biliary

Other procedural training

Endoscopic Ultrasound, University of Texas, Galveston, TX, November 2000

Enterex physician training, Amman, Jordan, September 7,2004

ABSTRACTS & PRESENTATIONS

1. *“Safety and Efficacy of Fluoroscopy-Guided Liver Biopsy as an Alternative to Other Guided Techniques “*

64th ACG annual meeting, Oct 19,1999, Phoenix, Arizona

2. *“Omeprazole Induced Iron Deficiency Anemia”*

64th ACG annual meeting, Oct 19,1999, Phoenix, Arizona

3. *“Case presentation: small bowel tumors”*

Pittsburgh Gut Club, April 10, 2000, Pittsburgh, PA

4. *“Incidental Significant findings on upper GI Endoscopy done for PEG placement”*

65th ACG annual meeting, Oct 16, 2000, New York, NY

5. *“Malignant Fibrous Histiocytosis of the Jejunum, case report and literature review”*

Practice Management Conference for Gastroenterology Fellows ASGE Oct 27, 2000, Santa Fe, NM

6. *“Case presentation: Extra intestinal manifestations of IBD”*
Pittsburgh Gut Club Nov 11, 2000, Pittsburgh, PA
7. *“Diagnostic yield of push enteroscopy in evaluation of patients with obscure GI bleeding”*
Practice management conference for Gastroenterology fellows ASGE Oct 12, 2001, Seattle, Washington
8. *“Role of Mycophenolate mofetil on Early Recurrence of Hepatitis C infection after liver transplantation “*
The second international congress on immunosuppression, Dec 6, 2001, San Diego, CA
9. *“Urea cycle Abnormalities”*
Phoenix Gastroenterological Society, Dec 12, 2001 Phoenix, AZ
10. *“Subclinical Myocardial ischemia as measured by Troponin T is common during liver transplantation”.*
American transplant Congress (ATC), April 30, 2002, Washington, DC
11. *“Treatment of Recurrent Hepatitis C (HCV) post Orthotopic Liver Transplantation (OLT) with Pegylated Interferon alpha- 2b and Ribavirin”.*
Presented as oral presentation at the 2002 transplant Fellow’s meeting, March 15, 2002 Irving, TX
12. *“Treatment of Recurrent Hepatitis C (HCV) post Orthotopic Liver Transplantation (OLT) with Pegylated Interferon alpha- 2b and Ribavirin”.*
Poster presentation Digestive disease week - DDW, May 21, 2002, San Francisco, CA
13. *“Subclinical Myocardial ischemia as measured by Troponin T is common during liver transplantation –an update”.*
The international liver transplant society (ILTS) annual meeting, June 14, 2002, Chicago, IL
14. *“Prolonged pre-transplant hospital stay does not increase VRE colonization in liver transplant recipients”*
International liver transplant society (ILTS) annual meeting, June 13, 2002, Chicago, IL
15. *“Combination of Pegylated interferon alpha- 2b and ribavirin in treatment of patients with recurrent hepatitis C post-liver transplantation: An update”*
Oral presentation at the international liver transplant society (ILTS) annual meeting, June 15, 2002, Chicago, IL
16. *“Role of ERCP in the evaluation and management of anastomatic strictures following liver transplantation: a single center experience”*
Oral presentation at American college of Gastroenterology 67th annual scientific

meeting, Oct 23 2002 Seattle, Washington

17. *“Role of ERCP in the evaluation and management of anastomatic strictures following liver transplantation: a single center experience”*

Presented at practice management conference for Gastroenterology fellows, Oct 4 2002 Scottsdale, AZ

18. *“Lactulose induced Pneumatosis coli: case report “*

American college of Gastroenterology 67th annual scientific meeting, Oct 23 2002 Seattle, Washington

19. *“Patterns of HCV Quasispecies transmission and evolution after liver transplantation predict the severity of HCV recurrence”*

American Association for Study of Liver Diseases (AASLD) annual meeting, Nov 5,2002 Boston, MA

20. *“Treatment with combination of PEG IFN alpha 2b and Ribavirin suppresses viral replication in liver transplantation recipients with recurrent HCV hepatitis”*

American Association for Study of Liver Diseases (AASLD) annual meeting, Nov 5,2002 Boston, MA

21. *“Updates in Hepatitis C”*

Jordan Society of American medical graduates, Sept 29, 2003 Amman, Jordan

22. *“Stenting for Gastrointestinal Malignancies”*

Jordan Oncology Society meeting, Oct 7, 2003 Amman, Jordan

23. *“What’s new in hepatitis C ”*

Hepatitis C awareness program for GP’s, Oct 15, 2003 Amman, Jordan

24. *“Liver diseases in pregnancy”*

Ground Round, Princess Basma Teaching Hospital, March 20 2004 Irbid, Jordan

25. *“Hepatitis C Genotype 4, The Middle East experience”*

Hungarian - Jordanian Experience Exchange Meeting, April 26 2004 Amman, Jordan

26. *“Updates in Hepatitis C”*

Schering Plugh sponsored meetings In May 16, 25 and 26, 2004 Amman Jordan

27. *“Stenting for esophageal malignancies”*

Jordanian Surgeons Society, May 24 2004, Amman, Jordan

28. *“Hepatitis B Update”*

Ground Round, King Hussein Cancer Center, June 14 2004, Amman, Jordan

29. *"Hepatitis B overview and treatment update"*
Irbid fourth Medical conference, June 26 2004, Irbid, Jordan.
30. *"General approach to reading motility studies"* clinical instructor and lecturer
Hands on course in esophageal motility, April 25-28, 2005, Damascus, Syria
31. *"Pathogenesis of portal hypertension"*
Postgraduate course in complications of Cirrhosis during the 19th Syrian congress of Gastroenterology April 29, 2005 Damascus, Syria
32. *"Update in Irritable Bowel Syndrome"*
Internal Medicine workshop, June 10 2005, Cairo, Egypt
33. *"IBS management and treatment"*
Internal Medicine workshop, July 16, 2005, Sednaya, Syria
34. *"Viral Hepatitis from A to E"*
Internal Medicine post graduate course, Jordan Society of American medical graduates, Sept 2, 2005 Amman, Jordan
35. *"NSAID's and the GI tract"*
Internal Medicine board review course, Sep 22, 2005 Limassol, Cyprus
36. *"Pathogenesis of portal hypertension"*
Monothematic conference: Varices from A to Z, March 16, 2006, Amman, Jordan
37. *"Management of distal colitis"*
The second Middle East IBD symposium, Dec 15, 2006, Dubai, UAE
38. *"Management of Biliary complications after liver transplantation and the role of ERCP"* The
17th international conference of internal Association of Surgeons and Gastroenterologist, Sept 8, 2007, Bucharest, Romania

PUBLICATIONS

1. *"Iron Deficiency Anemia: Induced by long term ingestion of Omeperazole"*
M.A. Khatib, MD; O. Rahim, MD; R. Kania, MD; P. Molloy MD
Digestive Diseases and Sciences 47(11): 2596-2597 Nov 2002
2. *"Fulminant Hepatic Failure"*
M. Edwyn Harrison, M. Amer Khatib and Jorge Rakela
Textbook chapter, Gastroenterologia Y Hepatologia, 3rd edition
3. *"Extrahepatic Manifestations of Hepatitis C"*
M. Amer Khatib, Majed Nusair and Mustafa Shennak

Jordan Medical Journal, May 2003; 37(1): 14-22

4. *“Treatment of recurrent Hepatitis C infection after liver Transplantation with combination of PEG-IFN α 2b and Ribavirin: An open label series”*

Amer Khatib, Hector Rodriguez-Luna, Pratima Sharma, Giovanni De Petris, James W. Williams, Jose Ortiz, Kathleen Hansen, David Mulligan, Adyr Moss, David D. Douglas, Jorge Rakela and Hugo E. Vargas
Transplantation. 2004 Jan 27; 77(2): 190-4

5. *“Nonalcoholic Steatohepatitis (NASH)”*

Walid Farah, Yousef Ajlouni, M. Amer Khatib and Mustafa Shennak
Jordan Medical Journal, Nov 2003; 37(2): 123-133

6. *“Acute hyperammonemia and encephalopathy in fifty-three-old man with previously undiagnosed Ornithine Transcarbamylase deficiency: case report and review of the literature”*

D. Galbreath, DL Roberts, BM Patel, T. Ingall, MA Khatib, D. Johnson
Submitted for publication at the Archives of Internal Medicine

7. *“Hepatitis C virus quasispecies dynamics predict fibrosis progression after liver transplantation”*

Juan Arenas, Juan F Gallegos, Tomasz Laskus, Jeff Wilkins, Amer Khatib, Carlos Fasola, Debra Adir, Marek Radowski, Karen Kibler, Marek Nowicki, David Douglas, James Williams, George Netto, David Mulligan, Goran Klintmalm, Jorge Rakela and Hugo Vargas
Journal of Infectious Diseases, June 2004 1; 189(11): 2037-46

8. *“Fulminant Liver Failure: Review”*

MA Khatib, ME Harrison
Jordan Medical Journal, Nov 2004; 38(2)

9. *“Effect of oral mycobalamin treatment on chest pain in patients with cobalamin deficiency and no evidence of coronary artery disease”*

M Zaqqa, Y Ismail, A Khatib, Y Bahou, H Daoud, M Saad and E Al-Mousa
Saudi Medical Journal, July 2005; 26(7); 447-8

PUBLISHED ABSTRACTS

1. *“Safety and Efficacy of Fluoroscopy-Guided Liver Biopsy as an Alternative to Other Guided Techniques “*

M. A. Khatib, M. Azzouz, D. Leff, R. Kania, P. Molloy, D. Van Thiel.
The American Journal of Gastroenterology

2. *“Omeprazole Induced Iron Deficiency Anemia”*

M. A. Khatib and P. Molloy
The American Journal of Gastroenterology

3. *“Incidental Significant findings on upper GI Endoscopy done for PEG placement”*
O. Rahim, M.A. Khatib, R. Kania, P. Molloy
The American Journal of Gastroenterology, Sept 2000, Vol 95(9), 2461
4. *“Malignant fibrous histiocytosis of the jejunum: a case report and literature review”*
M Khatib, J Smith, P Molloy, O Rahim, R Kania, G Geyer, J Homman
The American Journal of Gastroenterology, Sept 2000, Vol 95(9), 2496
5. *“Subclinical Myocardial ischemia as measured by Troponin T is common during liver transplantation”.*
M. A. Khatib, E. Carey, H. Vargas, V. Balan, D. Mulligan, A. Moss, J. Rakela, H. Harrison, D. Douglas
Liver transplantation, June 2002, Vol 8 (6), C-30, A118
6. *“Treatment of Recurrent Hepatitis C (HCV) post Orthotopic Liver Transplantation (OLT) with Pegylated Interferon alpha- 2b and Ribavirin”.*
M. A. Khatib, M. Rosati, E. Carey, H. Harrison, D. Mulligan, A. Moss, V Balan, D. Douglas, J. Rakela, Vargas, V
Liver transplantation, June 2002, Vol 8 (6), C-63, A250
7. *“Prolonged pre-transplant hospital stay does not increase VRE colonization in liver transplant recipients”*
E. Carey, L. Yancy, J. Blair, D. Douglas, M. A. Khatib, H. Harrison, H. Vargas, V. Balan, J. Rakela
Liver transplantation, June 2002, Vol 8 (6), C-13, A50
8. *“Treatment with combination of PEG IFN alpha 2b and Ribavirin suppresses viral replication in liver transplantation recipients with recurrent HCV hepatitis”*
M.A.Khatib, J. Arenas, E. Carey, A. Moss, D. Mulligan, J. Ortiz, K. Hansen, M. Harrison, D. Douglass, V. Balan, J Rakela, H.E.Vargas.
Hepatology Vol 36, No 4, 182A, Oct 2002
9. *“Role of ERCP in the evaluation and management of anastomatic strictures following liver transplantation: a single center experience”*
M.A.Khatib, V. Balan, D. Douglas, D. Mulligan, M. Anderson, H. Vargas, E. Carey, M.E. Harrison
The American Journal of Gastroenterology, September 2002, Vol 97 (9) S 196
10. *“Patterns of HCV Quasispecies transmission and evolution after liver transplantation predict the severity of HCV recurrence”*
J. Arenas, M.A.Khatib, H. Groninger, J. Wilkinson, J. Williams, D. Mulligan, D. Douglass, G. Netto, C. Fasola, T. Laskus, G. Klintmalm, J Rakela, H.E.Vargas.
Hepatology Vol 36, No 4, 179A, Oct 2002

11. *“A Case of Pneumatosis custodies intestinalist “*
E. Carey, M.A. Khatib, DD. Douglas, M.E. Harrison
The American Journal of Gastroenterology, September 2002, Vol 97 (9) S 92
12. *“Prevalence and clinical significant of elevated alpha-fetoprotein in non cirrhotic patients with Hepatitis C”*
E. Carey, M. Rosati, M. A. Khatib, M. Harrison, M. Anderson, H. Vargas, J. Rakela, V. Balan
Hepatology Vol 36, No 4, 564A, Oct 2002
13. *“Use of Erythropoietin allows for optimal Ribavirin dosing during therapy for Hepatitis C virus with Pegylated Interferon and Ribavirin”*
E. Carey, M. Rosati, M. A. Khatib, H. Vargas, M. Harrison, M. Anderson, D. Douglas, J. Rakela, V. Balan
Hepatology Vol 36, No 4, 604A, Oct 2002
14. *“Use of G-CSF allows for optimal PEG- INF dosing during therapy for Hepatitis C virus with Pegylated Interferon and Ribavirin”*
E. Carey, M. Rosati, M. Anderson, M. A. Khatib, H. Vargas, M. Harrison, D. Douglas, J. Rakela, V. Balan
Hepatology Vol 36, No 4, 564A, Oct 2002
15. *“Hepatopulmonary syndrome resolves after living donor liver transplantation”*
E. Carey, M. A. Khatib, D. Douglas, H. Vargas, M. Harrison, V. Balan, M. Harrison, J. Rakela, A. Moss, D. Mulligan
Hepatology Vol 36, No 4, 665A, Oct 2002

ACTIVE RESEARCH

1. Vitamin B12 deficiency in Jordan, prevalence and etiology
2. The use of Alternative and Complementary medicine among IBS patients
3. Cirrhosis in Jordan: causes, stages at presentation and the need of transplantation in Jordan
4. The role of HIDA scan in assessing the disease activity in patients with NASH

CLINICAL TRIALS

1. A Trial to Evaluate the Long-term Tolerability, Safety, Satisfaction, Pharmacokinetics, and Use Patterns of Oral R108512 Tablets in Subjects with Chronic Constipation
2. A Two-Period, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Re-treatment of Prucalopride on Efficacy and Safety in Subjects with Chronic Constipation

3. Double-Blind, Placebo-Controlled, Randomized, Multicenter, Parallel-Group Dose-Ranging Study to Investigate the Efficacy and Safety of Cilansetron in Non-Constipated Patients with Irritable Bowel Syndrome
4. Double-Blind, Placebo-Controlled Long-Term Extension Study to Evaluate the Nine Month Safety Profile of Cilansetron in Non-Constipated IBS Patients
5. Induction therapy with Infergen in the Treatment of Patients with Chronic Hepatitis C and an Examination of the Role of Ido and Tryptophan Catabolism in Interferon-Related Depression.
6. A Study of the Efficacy and safety of INKP-100-301 (Sodium Phosphate Tablets) compared to NuLYTELY as a Purgative agent for patients undergoing colonoscopic evaluation.
7. Multicenter Randomization trial of 15 mcg Infergen (Interferon Alfacon-1) administered daily vs Thrice weekly in patients with Hepatitis C who did not respond to Interferon therapy.
8. A 24 week randomized, Open label study of health care resource use, Quality of life and productivity with Alosetron 1 mg twice daily versus traditional therapy in females with Diarrhea-predominant irritable bowel syndrome.
9. A Randomized Study of Celecoxib for Prevention of New Sporadic Adenomatous Colorectal Polyps in Patients Who Have Undergone Polypectomy.
10. Comparison of Standard Therapy of Intron A + Ribavirin to Induction Combination Therapy for Treatment of Patients with Chronic Hepatitis C not Previously Treated with Interferon (Ferrantino)
11. PEG Intron + Ribavirin for the Treatment of Patients with Chronic Hepatitis (Krawitt).
12. An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding after Successful Hemostasis
13. A Phase III, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study of the Effects of a Somatostatin Analogue (Lanreotide) as an Adjuvant to Endoscopic Band Ligation of Patients with Acute Bleeding from Esophageal Varices"
14. A Multi-Center Study of the Safety and Efficacy of N-Acetylcysteine in the Treatment of Acute Liver Failure Not Caused By Acetaminophen"